

DAFTAR PUSTAKA

1. Welliver C, Helo S, McVary KT. Technique considerations and complication management in transurethral resection of the prostate and photoselective vaporization of the prostate. *Transl Androl Urol.* 2017;6(4):695–703.
2. Gravas S, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms Benign Prostatic Obstruction (BPO). *Eur Assoc Urol.* 2012;64:118–40.
3. Fitzpatrick JM, Desgrandchamps F, Adjali K, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. *BJU Int.* 2012;109(1):88–95.a
4. Anutrakulchai S. Residual LUTS after Transurethral Resection of Prostate (TURP): The Urodynamic Studies in Chiangmai University. *Thai J Surg.* 2005;26:82–7.
5. Zhang Z, Cao Z, Xu C, et al. Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors. *Urology* 2014;84:117–121.
6. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. *Int Urogynecol J.* 2012;23(8):975–82
7. Anger JT, Goldman HB, Luo X, Carlsson MO, Chapman D, Zou KH, et al. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. *Neurourol Urodyn.* 2018;37(1):213–22.
8. Agarwal A, Dhiraaj S, Singhal V, et al. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. *Br J Anaesth,* 2006,96(3):377-380
9. Yadav G, Prashanth M, Singh RB, Jain G, Singh Y, Meena RK. Incidence and severity of catheter related bladder discomfort by using different inhalational anesthetic agents and comparing it with propofol. *Anaesth Pain & Intensive Care* 2015; 19(4):452-456

10. Hu B, Li C, Pan M, Zhong M, Cao Y, Zhang N, et al. Strategies for the prevention of catheter-related bladder discomfort. *Medicine(Baltimore)*. 2016; 95(37) : e4859.
11. Bai Y, Wang X, Li X, Pu C, Yuan H, Tang Y, et al. Management of Catheter-Related Bladder Discomfort in Patients Who Underwent Elective Surgery. *J Endourol*. 2015;29(6):640–9.
12. Andersson KE. Detrusor myocyte activity and afferent signaling. *Neurourol Urodyn* 2010;29:97–106
13. Srivastava VK, Agrawal S, Kadiyala VN, Ahmed M, Sharma S, Kumar R. The efficacy of pregabalin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled double-blind study. *J Anesth*. 2015;29(2):212–6.
14. Li J yi, Liao R. Prevention of catheter-related bladder discomfort - pudendal nerve block with ropivacaine versus intravenous tramadol: Study protocol for a randomized controlled trial. *Trials*. *Trials*; 2016;17(1):1–6.
15. Bai Y, Wang X, Li X, et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery. *J Endourol*. 2015;29:640–649.
16. Maro S, Zarattin D, Baron T, Bourez S, de la Taille A, Salomon L. Catheter-related bladder discomfort after urological surgery: Importance of the type of surgery and efficiency of treatment by clonazepam. *Prog Urol* 2014;24: 628–633.
17. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Facteurs prédictifs d'inconfort de sonde vésicale en salle de réveil. *Ann Fr Anesth Reanim*. Elsevier Masson SAS; 2011;30(2):122–5.
18. Li C, Liu Z, Yang F. Predictors of catheter-related bladder discomfort after urological surgery. *J Huazhong Univ Sci Technol - Med Sci*. 2014;34(4):559–62.
19. Manley K V., Hubbard R, Swallow D, Finch W, Wood SJ, Biers SM. Risk factors for development of primary bladder squamous cell carcinoma. *Ann R Coll Surg Engl*. 2017;99(2):155–60.

20. Birder L, Andersson K-E. Urothelial Signaling. *Physiological Reviews*. 2013;93(2):653-680.
21. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. *BJU Int*. 2008;101(suppl 3):17-21.
22. Oelke M, Hofner K, Jonas U, et al. Benign prostatic hyperplasia: terminology and assessment. *Dtsch Arztebl* 2007;104(33): A 2261-7.
23. Chapple C, Abrams P. Male lower urinary tract symptoms (LUTS) an international consultation on male LUTS Fukuoka, Japan, September 30-October 4, 2012. Montreal: Societe Internationale d'Urologie. 2013.hal.42-3.
24. Briolat GM. Benign prostatic hyperplasia. *Nurse Pract Urol*. Macmillan Publishers Limited; 2016;2:117–26.
25. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. *J Urol* 2005, 173:1256–61.
26. Data pasien BPH RSCM tahun 1994-2013
27. Data pasien BPH RSHS tahun 2012-2016. Diakses Februari 2017 (Belum dipublikasi)
28. Parsons JK: Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. *Curr Bladder Dysfunct Rep*. 2010;5:212–18.
29. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: New approaches to old problems. *J Urol*. 2007;178:395–401.
30. Kaplan SA, O'Neill E, Lowe R, Hanson M, Meehan AG. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: Data from the Proscar Long-term Efficacy and Safety Study (PLESS) Aging Male. 2013;16:48–51
31. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhaus ML, Goodman PJ, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the prostate cancer prevention trial. *Am J Epidemiol*. 2008;168:1416–24.

32. Nandeesh H. Benign Prostatic Hyperplasia: dietary and metabolic risk factors. *Int Urol Nephrol* (2008) 40: 649-56.
33. Parsons JK, Kashefi C. Physical Activity , Benign Prostatic Hyperplasia , and Lower Urinary Tract Symptoms. *Eur Urol*. 2008;53(6):1228–35.
34. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. *Am J Epidemiol*. 2008;167(8):925–34.
35. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III) Prostate. 2005;62:27–33.
36. Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. *Eur Urol*. 2008;54:1379–84.
37. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men. *Prostate*. 2007;67:1816–24.
38. Soni A, Bansal A, Mishra AK, Batra J, Singh LC, Chakraborty A, et al. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. *Genet Test Mol Biomarkers*. 2012;16:835–40.
39. Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. *BJU Int*. 2004;94:332–4.
40. Purnomo B. Basuki. *Dasar-dasar Urologi*. Ed 3. Jakarta: Penerbit Buku CV Sagung Seto, 2011; hlmn 125-144.
41. Foster, CS. Pathology of benign prostatic hyperplasia. *Prostate Suppl*. 2000;9: 4–14 .

42. Niu, Y. et al. Proliferation and differentiation of prostatic stromal cells. *BJU Int.* 2001;87, 386–393.
43. Carson, C. 3rd & Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. *Urology.* 2003;61:2–7.
44. Chughtai, B., Lee, R., Te, A. & Kaplan, S. Inflammation and benign prostatic hyperplasia: clinical implications. *Curr Urol Rep.* 2011; 12, 274–277.
45. Robert, G. et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. *Prostate.* 2009; 69: 1774–1780.
46. Wang, W., Bergh, A. & Damber, J. E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. *Prostate.* 2004;61: 60–72.
47. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: Evaluation and medical management in primary care. *Cleve Clin J Med.* 2017; 84(1):53–64.
48. Roehrborn, C. G. & Schwinn, D. A. α 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. *J. Urol.* 2004; 171: 1029–1035.
49. Andersson, K.-E. α -Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α -adrenoceptor antagonists. *World J. Urol.* 2002; 19: 390–396.
50. Siroky, M. B. The aging bladder. *Rev. Urol.* 2004; 6: S3–S7.
51. Briolat GM. Benign prostatic hyperplasia. *Nurse Pract Urol.* 2016;2:117–26.
52. Levin, R. M. et al. Obstructive response of human bladder to BPH versus rabbit bladder response to partial outlet obstruction: a direct comparison. *Neurourol. Urodynam.* 2000; 19: 609–629.
53. Gerber GS, Brendler CB. Evaluation of the Urologic Patient:History, Physical Examination, and Urinalysis. In: *Campbell-Walsh Urology.* 10th Edition. Philadelphia: Elsevier Saunders 2012; p. 71-80.
54. McVary KT, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol.* 2011;185(5):1793-803.

55. Gravas S, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms Benign Prostatic Obstruction (BPO). *Eur Assoc Urol.* 2012;64:118–40.
56. D'Silva KA, Dahm P, Wong CL. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. *JAMA.* 2014;312(5):535-42.
57. Presti JC . Neoplasm of the prostate gland Neoplasma in prostate gland. in McAninchh JW, Lue TF (eds) . *Smith and Tanagho's General Urology* . 16th ed . New York : Lange Medical Book/McGraw-Hill; 2003. p. 267-276
58. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: Evaluation and medical management in primary care. *Cleve Clin J Med.* 2017;84(1):53–64.
59. McNicholas TA, Kirby RS, Lepor H. and non-surgical management of benign prostatic hyperplasia. *Campbell's urology.* 10th ed. Philadelphia: WB Saunders Co., 2012. 2612 - 2640.
60. Welliver C, Helo S, McVary KT. Technique considerations and complication management in transurethral resection of the prostate and photoselective vaporization of the prostate. *Transl Androl Urol.* 2017;6(4):695–703.
61. Macey MR, Raynor MC. Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. *Semin Intervent Radiol.* 2016;1(212):220–1.
62. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: Minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. *J Urol* 2005;174:1887-91.
63. Chughtai B, Simma-Chiang V, Kaplan A S. Evaluation and Management of Post-Transurethral Resection of the Prostate Lower Urinary Tract Symptoms. Department of Urology, Weil Cornell Medical College, New York. *Curr Urol Rep* (2014) 15;434.

64. Burke, N., et al. Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. *Urology*. 2010. 75: 1015.
65. Golam Robbani A.B.M., Salam M. A., Anowarul Islam A. K. M. Transurethral Resection (TURP) Versus Transurethral Incision (TUIP) of the Prostate for Small Sized Benign Prostatic Hyperplasia: A Prospective Randomized Study. *TAJ*. 2006; 19(2): 50-56.
66. Christidis D, Mcgrath S, Perera M, Manning T, Bolton D, Lawrentschuk N. Minimally invasive surgical therapies for benign prostatic hypertrophy : The rise in minimally invasive surgical therapies. *Prostate Int*. Elsevier Ltd; 2017;5(2):41–6.
67. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. *Eur Urol*. 2012;61(5):917-25.
68. Speakman MJ, Cheng X. Management of the complications of BPH/BOO. *Indian J Urol*. 2014;30(2):208-13.
69. Gravas S, T Bach, Bachmann A, et al. EAU Guidelines on the Management of NonNeurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2016.
70. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU Int* 2011; 108: 1132–8
71. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006; 50: 1306–15.
72. Tirtayasa PMW, Rahardjo HE. A survey on the management of overactive bladder by Indonesian urologists. *Med J Indones*. 2015;24(2):91–6.
73. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. *Int Urogynecol J*. 2012;23(8):975–82.
74. Brading A. Overactive bladder: why it occurs. *Women’s Health Med*. 2005; 2: 20–3.

75. Brading AF, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. *Adv Exp Med Biol.* 2003; 539: 255–69.
76. Sui G, Fry CH, Malone-Lee J, Wu C. Aberrant Ca²⁺ oscillations in smooth muscle cells from overactive human bladders. *Cell Calcium.* 2009; 45: 456–64.
77. Kessler TM, Burkhard FC, Z'Brun S et al. Effect of thalamic deep brain stimulation on lower urinary tract function. *Eur Urol.* 2008; 53: 607–12.
78. Hougaard C, Fraser MO, Chien C et al. A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. *J Pharmacol Exp Ther.* 2009; 328: 28–39.
79. Shioyama R, Aoki Y, Ito H et al. Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE₂ levels in the rat. *Am J Physiol Regul Integr Comp Physiol* 2008; 295: R714–8.
80. Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. *Curr Urol Rep* 2008; 9: 284–90.
81. Alberti KG, Zimmet P, Shaw J et al. The metabolic syndrome—a new worldwide definition. *Lancet.* 2005; 366(9491): 1059–62.
82. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). *Int J Obes (Lond).* 2005; 29: 310–6.
83. Lee WC. The impact of diabetes on the lower urinary tract dysfunction. *JTUA* 2009; 20: 155–61.
84. Liu RT, Chung MS, Lee WC et al. Prevalence of Overactive Bladder (OAB) and associated risk factors in 1,359 patients with type 2 diabetes. *Urology* 2011; 78: 1040–5.
85. Tong YC, Cheng JT. Alterations of M_{2,3}-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. *J Urol* 2007; 178: 1537–42

86. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. *J Urol*. 2008; 179: 2470–6.
87. Lee WC, Chuang YC, Chiang PH, Chien CT, Yu HJ, Wu CC. Pathophysiological studies of overactive bladder and bladder motor dysfunction in a rat model of metabolic syndrome. *J Urol*. 2011; 186: 318–25.
88. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. *Neurourol Urodyn*. 2010; 29: 1350–4.
89. Azadzo KM, Shinde VM, Tarcan T et al. Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. *J Urol* 2003; 169: 1885–91.
90. Azadzo KM, Radisavljevic ZM, Golabek T et al. Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. *J Urol* 2010; 183: 362–9.
91. Yang SSD, Wang CC, Hsieh JH, Chen YT. α 1-Adrenergic blockers in young men with primary bladder neck obstruction. *J Urol* 2002; 168: 571–4.
92. Kupelian V, McVary KT, Barry MJ et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston area community health survey. *Urology* 2009; 73: 950–7.
93. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P. Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. *Urol Sci* 2010; 21: 132–6.
94. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats—effects of bladder outlet obstruction and intravesical PGE2. *Neurourol Urodyn* 2008; 27: 88–95.
95. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, Yokoyama O, et al. Assessment of overactive bladder symptoms:

comparison of 3-day bladder diary and the overactive bladder symptoms score. *Urology*. 2011;77:60–4.

96. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults : AUA / SUFU Guideline. *JURO*. Elsevier Inc.; 2012;188(6):2455–63.
97. Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schröder A, Tubaro A: EAU Guidelines on Urinary Incontinence. *Actas Urol Esp*. 2011;35:373–388.
98. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, Obara K, Gotoh M, Igawa Y, Seki N, Yoshida M: Clinical guidelines for overactive bladder. *Int J Urol* 2009;16:126–142.
99. Hashim H, Abrams P: How should patients with an overactive bladder manipulate their fluid intake? *BJU Int* 2008;102:62–66.
100. Lohsiriwat S, Hirunsai M, Chaiyaprasithi B: Effect of caffeine on bladder function in patients with overactive bladder symptoms. *Urol Ann* 2011;3:14–18.
101. Kurita N, Yamazaki S, Fukumori N, et al. Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. *BMJ Open*. 2013;3(5).
102. Lai H, Gardner V, Vetter J, Andriole GL. Correlation between psychological stress levels and the severity of overactive bladder symptoms. *BioMed Cent Urol*. 2015;1–7.
103. Ramakrishnan K, Mold J. Urinary Catheters : A Review. *Internet J Fam Pract*. 2012;3(2):1–12.
104. Nazarko L. Catheter care in the community. *Nurse Stand*. 2008;14:46–51.
105. Bai Y, Wang X, Li X, et al. Management of Catheter-Related Bladder Discomfort in Patients Who Underwent Elective Surgery. *J Endourol*. 2015;29(6):640-9.
106. Soper, D.S. (2018). A-priori Sample Size Calculator for Hierarchical Multiple Regression.

107. Cohen, J, Cohen, P, West, S.G, and Aiken, L.S. (2003). *Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences* (3rd edition). Mahwah, NJ: Lawrence Earlbaum Associates.
108. Sumardi R, Mochtar CA, Santoso BI. Test-retest Reliability of the Indonesian Version of the Overactive Bladder Symptom Score (OABSS) and Its Correlation with Standard Assessment Tools. *Acta Medica Indones Indones J Intern Med.* 2012;44(3):214–21.
109. Liu TT, Thomas S, Mclean DT, et al. Prostate enlargement and altered urinary function are part of the aging process. *Aging (Albany NY).* 2019;11(9):2653–2669.
110. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev.* John Wiley & Sons, Ltd; 2019 ;(5).
111. Mayer, E. K., Kroeze, S. G., Chopra, S., Bottle, A., & Patel, A. (2012). Examining the ‘gold standard’: A comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. *BJU International*, 110(11), 1595—1601.
112. Kusljic S, Aneja J, Manias E. Incidence of complications in men undergoing transurethral resection of the prostate. *Collegian. Australian College of Nursing Ltd;* 2017;24(1):3–9.
113. Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. *Ci Ji Yi Xue Za Zhi.* 2017;29(2):79–83.
114. Shah J. Catheterisation. *Ann R Coll Surg Engl.* 2012;94(1):5–7.
115. Dougherty JM, Aeddula NR. Male Urinary Retention. [Updated 2019 Jun 30]. In: *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2019 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538499/>
116. Akhavizadegan H. A Novel Technique for Post-Prostatectomy Catheter Traction. *Nephrourol Mon.* 2016;8(4):e37394.

117. Abdelrahman M, Davis NF, McMahon BP, et al. A comparative assessment of irrigation and drainage characteristics for commercially available urethral catheters. *Cent European J Urol*. 2017;70(4):382–387.
118. Agbugui JO, Obarisiagbon EO, Osaigbovo II. Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia. *Niger J Surg*. 2016;22(2):65–69.
119. Pourmand G, Abedi AR, Karami AA, Khashayar P, Mehrsai AR. Urinary infection before and after prostatectomy. *Saudi J Kidney Dis Transpl*. 2010;21:290–4.
120. Parsons JK, Sarma AM, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. *J Urol*. 2013;189:S102–6.
121. Khoubehi B, Watkin NA, Mee AD, Ogden CW. Morbidity and the impact on redaily activities associated with catheter drainage after acute urinary retention. *BJU Int*. 2000;85:1033–1036
122. Ugare UG, Bassey IA, Udosen EJ, Essiet A, Bassey OO. Management of lower urinary retention in a limited resource setting. *Ethiop J Health Sci*. 2014;24(4):329–336.
123. Desgradchamps F, Dela Taille A, Doublet JD. The management of acute urinary retention in France; a cross sectional survey in 2,618 men with benign prostatic hyperplasia. *BJU (int)* 2006;97:727–733.
124. Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. *Neurourol Urodyn*. 2011;30(7):1309-1314.
125. De Nunzio C, Franco G, Rocchegiani A, et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. *J Urol* 2003;169:535–9
126. Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. *Ther Adv Urol*. 2017;10(2):79–92. Published 2017 Dec 7.

127. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. *Curr Urol*. 2018;11(3):117–125.
128. Wan Q, Xiong G, Liu G, Shupe TD, Wei G, Zhang D, et al. Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction. *Stem Cell Res Ther. Stem Cell Research & Therapy*; 2018;9(1):304.
129. Birder L, WC de G. Mechanism of Disease: involvement of the urothelium in bladder dysfunction. *Nat Clin Pr Urol*. 2011;4(1):46–54.
130. Fry CH, Vahabi B. The Role of the Mucosa in Normal and Abnormal Bladder Function. *Basic Clin Pharmacol Toxicol*. 2016;119 Suppl 3(Suppl 3):57–62.
131. Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. System in the Bladder. 2017;13(4):193–204.

